AU645668B2 - Mixed pyridine-2,4-and-2,5-dicarboxamides, a process for preparing them, the use thereof and pharmaceuticals based on these compounds - Google Patents
Mixed pyridine-2,4-and-2,5-dicarboxamides, a process for preparing them, the use thereof and pharmaceuticals based on these compounds Download PDFInfo
- Publication number
- AU645668B2 AU645668B2 AU12967/92A AU1296792A AU645668B2 AU 645668 B2 AU645668 B2 AU 645668B2 AU 12967/92 A AU12967/92 A AU 12967/92A AU 1296792 A AU1296792 A AU 1296792A AU 645668 B2 AU645668 B2 AU 645668B2
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- formula
- unsubstituted
- compound
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Photoreceptors In Electrophotography (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to mixed pyridine-2,4- and -2,5-dicarboxylic acid diamides, the carboxylic acid amide group in position 2 being a primary acid amide. The said compounds are suitable for the inhibition of proline hydroxylase and lysine hydroxylase and are used as fibrosuppressants and immunosuppressants.
Description
P/00/01i 2015mft Regulation 3.2(2)
AUSTRALIA
Patents Act 1990 4 *6D8
ORIGINAL
COMPLETE SPECIFICATION STANDARD PATENT Application V'amber: Lodged,
S.
S
@0.
@5 0 S S OS 5* 0 S S 0S
S
Invention Title: MIXED PYRIDINE-2,4-AND-2,5-DICARBOXAMIDES, A PRCESS FOR PREPARING THEM, THE USE THEREOF AND PHARMACEUTICALS BASED ON THESE COMPOUNDS 5S ft S S *5 *5S9 50 S. S 50 0 5 0 The following statement is a full description of this invention, including the best method of performing it known to
S.
S
S..
Q *SS6S S S HOECHST AKTIENGESELLSCHAFT HOE 91/F 079 Dr.FI/pl Description Mixed pyridine-2,4- and -2,5-dicarboxamides, a process for preparing them, the use thereof and pharmaceuticals based on these compounds Compounds which inhibit proline hydroxylase and lysine hydroxylase effect a very selective inhibition of collagen biosynthesis due to influencing collagenspecific hydroxylation reactions. In the course thereof, protein-bound proline or lysine is hydroxylated by the enzymes proline hydroxylase or lysine hydroxylase respectively. If this reaction is suppressed by inhibitors, the resulting collagen molecule is unable to 15 function, is insufficiently hydroxylated and can be released by the cells only in small amounts into the eeo. extracellular space. The insufficiently hydroxylated collagen cannot, moreover, be incorporated in the collagen matrix and is very easily broken down by proteolysis. The consequence of these effects is an overall reduction in the amount of collagen deposited in the extracellular space.
It is known that inhibition of proline hydroxylase by known inhibitors such as a,a'-dipyridyl results in us inhibition of C1' biosynthesis by macrophages MUller et al., FEBS Lett. 90 (1978), 218; Immunobiology 155 (1978), 47). This results in the classical pathway of complement activation becoming inoperative. Hence inhibitors of proline hydroxylase act as immunosuppres- 30 sants, for example in immune complex diseases.
It is known that proline hydroxylase can be effectively inhibited by pyridine-2,4- and -2,5-dicarboxylic acids Mayama et al., Eur. J. Biochem. 138 (1984) 239-245).
However, in cell culture, these compounds are effective inhibitors only in very high concentrations (Tschank, G.
2 et al., Biochem. J. 238 (1987) 625-633).
DE-A 34 32 094 describes pyridine-2,4- and dicarboxylic disesters with 1-6 carbon atoms in the ester alkyl moiety as pharmaceuticals for the inhibition of proline hydroxylase and lysine hydroxylase.
These lower alkylated diesters have the disadvantage, however, that they are too rapidly cleaved in the body to the acids and do not reach their site of action in the cell in sufficiently high concentration and thus are less suitable for possible administration as pharmaceuticals.
DE-A 37 03 959, DE-A 37 03 362 and DE-A 37 03 963 describe in a general form mixed esters/amides, higher alkylated diesters and diamides of pyridine-2,4- and 2 ,5-dicarboxylic acids which are effective inhibitors of Sg. 15 collagen biosynthesis in animal models.
Thus, DE-A 37 03 959 describes, inter alia, the synthesis of N,N'-bis(2-methoxyethyl)pyridine-2,4-dicarboxamide and N,N'-bis(3-isopropoxypropyl)pyridine-2,4-dicarboxamide.
GermanPatent Applications P 38 26 471.4 and P 38 28 140.6 propose an improved process for preparing N,N'-bis(2methoxyethyl)pyridine-2,4-dicarboxamide. German Patent Application P 39 24 093.2 proposes novel N,N'bis(alkoxyalkyl)pyridine-2,4-dicarboxamides.
e The object to be achieved was thus to find compounds which are suitable in a much improved manner than those hitherto disclosed for the inhibition of proline hydroxylase and lysine hydroxylase. The object has been achieved by pyridine-2,4- and -2,5-dicarboxamides of the formula 0 2 -1N-- 3 0 1 C-NH2 R6 3 in which
R
1 is C 1
-C
12 -alkyl, C 2
-C
12 -alkenyl or C 2
-C
1 2 -alkynyl, which are unsubstituted or substituted once or, in the case of the C 2
-C
12 -alkyls, C 2
-C
12 -alkenyls and C 2
-C
12 alkynyls, also several times by halogen, hydroxyl, cyano, amino, carboxyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkylor dialkylamino, where the alkyl radicals have 1- 4 carbon atoms, or by indolyl or phenyl, which is unsubstituted or substituted once, twice or three times by halogen, nitro, Ci-C 4 -alkyl or Ci-C 4 -alkoxy, it also being possible in the case of multiple substitutions for the substituents to be independently 15 different from one another, or R I is saturated C 5
-C
7 -cycloalkyl which is optionally benzo-fused, or R 1 is aryl or heteroaryl, which is unsubstituted or in turn substituted once, twice or three times by halogen, nitro, cyano, Ci-C 4 -alkyl or Ci-C 4 alkoxy, it also being possible in the case of multiple substitutions for the substituents to be independently different from one another, or provided that R 2 is H, R 1 is amino which is unsubstituted or mono- or disubstituted by C 1
-C
4 alkyl, phenyl or Ci-C 3 -alkylcarbonyl, a and
R
2 is hydrogen or R 1 where R 2 and R 1 are identical or different, -4 or where the radicals R1 and R 2 form, together with the nitrogen atom, a radical of the formula \N
(CH
2 )n in which n isl1to 3and x iSo0, S, CH 2 or N-R 3 where R 3 is hydrogen, phenyl or Cl-C-alkyl, C 2
-C
6 -alkenyl or
C
2
-C'
6 -alkynyl, wheir -hese phenyl, alkyl, alkenyl and alkynyl radicals are unsubstituted or substituted ilia*"one or more times by: phenyl which in turn is unsubstituted or substituted *.:one or more times by one or more substituents *.**selected from: halogen, nitro, cyano, carboxyl, hydroxyl, methyl, ethyl, methoxy, ethoxy and trifluoromethyl, or N )21 where
R
4 is H or C 1 C-alkyl, or I COOR 5 where R R 5 is H or Cl-C 3 -alkyl, or CON (R 6 2 or CONHR 6 where Rb is H or Cl-C-alkyl, or where (R 6 2 is a C 4
-C
6 5 alkylene chain in which zero or one CH 2 group which is not directly adjacent to the nitrogen atom is replaced by 0, S or N-R 4 or where
R
3 is Ci-C 4 -alkoxycarbonyl or C 3
-C
7 -cycloalkyl, and the physiologically tolerated salts, which likewise effectively inhibit lysine hydroxylase and proline hydroxylase in animal models.
The invention particularly relates to pyridine-2,4- and -2,5-dicarboxamides of the formula I in which '6 e e ,f S R is Ci-C 1 2 -alkyl which is unsubstituted or substituted once or, in the case of the C 2
-C
12 -alkyls, also several times by phenyl, hydroxyl, alkoxy, amino, alkoxycarbonyl, alkyl- or dialkylamino, where the alkyl radicals have 1-3 carbon atoms, or 20
R
1 is phenyl which is unsubstituted or in turn substituted once by halogen, nitro, cyano, methyl or methoxy, provided that R 2 is H, R 1 is amino which is unsubstituted or monosubstituted by Ci-C 3 -alkyl, phenyl or C-C 3 -alkylcarbonyl, or,
C.
8 9e 9.
CC.
a,,
O~
and
R
2 is hydrogen, or where the radicals R' and R 2 form, together with the nitrogen atom, a radical of the formula -N X 6 in which X is O, CH 2 or N-R 3 where
R
3 is hydrogen, or Ci-C 3 -alkyl, and the physiologically tolerated salts.
The meanings of halogen are fluorine, chlorine, bromine and iodine, those of aryl are, phenyl and naphthyl, and those of heteroaryl are 5- and 6-membered aromatic rings with 1, 2 or 3 nitrogen and/or oxygen and/or sulfur atoms, which can also be benzo-fused where appropriate; the heteroaryl radicals are, in particular, pyridyl, pyridazyl, pyrimidyl, pyrazyl, 1,3,5-triazyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, thienyl, oxazolyl and thiazolyl radicals and, where appropriate, the benzo- 15 fused compounds thereof.
*Goes: "Substituted several times" means hereinbefore and hereinafter that at least 2, not more than 4, hydrogen atoms present in the alkyl, alkenyl, alkynyl, heteroaryl and aryl radicals are replaced by the substituents "20 mentioned. In the case of multiple substitutions the substituents can also be independently different from one another.
All alkyl and alkenyl radicals mentioned with more than 2 carbon atoms and all alkynyl radicals with more than 3 "*25 carbon atoms can be both straight-chain and branched.
The invention further relates to the compounds of the formula I for use as pharmaceuticals. The invention additionally relates to the compounds of the formula I for use as fibrosuppressants and immunosuppressants and for the inhibition of proline hydroxylase and lysine hydroxylase and for influencing the metabolism of 7 collagen and collagen-like substances and the biosynthesis of Cl. Inhibitors of proline hydroxylase are suitable tools in the therapy of diseases in which the deposition of collagens makes a crucial contribution to the clinical picture. These include, inter alia, fibroses of the lungs, liver and skin (scleroderma) and atherosclerosis.
The pyridine-2,4- and -2,5-dicarboxamides of the formula I which are substituted exclusively in position 4 or 5 in the amide group show a considerable and surprising improved activity in inhibiting proline hydroxylase and lysine hydroxylase in animal experiments compared with the pyridine-2,4-dicarboxamides substituted in position also by carboxamide groups from DE-A-3 707 429 and 15 compared with the pyridine-2,4- and S. substituted in both amide groups of DE-A 37 039 59.
The invention further relates to a process for the preparation of compounds of the formula I, which com- S.prises reacting a compound of the formula II' Y 0
(II')
s N 0 2
CH
3 with a compound of the formula III I1
R
"(III)
H-N
where R 1 and R 2 have the meanings indicated for formula I, and Y is halogen, especially chlorine, and subsequently converting the resulting compound of the formla IV 8- 0
(IV)
C -N R R 2 N CO 2
CH
3 with N-1 3 into a compound of the formula I 0 g-N
R
1
R
2 N C -NH, *0 S.f followed, where appropriate, by conversion into its physiologically tolerated salts.
The following reaction diagram shows the preparation route (stages 5 and including the synthesis of the precursors (1 to 4) &*fee 0 9- Reaction diagram C0 2
H
N C0 2
H
CO *12- N CO CH,-- -tag Stagage 4 2 lw *see so C co 2 ci- 2 N
CO
2
CH
3 N C0 2
H
Stage 3 Stage 4 *5 S S S
S.
S *5 C 55
S
.5
C*S
5555 0 C0 2
H
N
CONR
1
R
2 (11) C0 2
CH
3 Stage R2
N
(IV)
CO
2
CH
3 NH3/ M~e OH Stage
CONR
1
R
2
CONH
2 10 In stage 1, commercially available pyridine-2,4dicarboxylic acid is converted into its dicarbonyl dihalide, preferably its dichloride, and reacted with an optionally substituted benzyl alcohol to give dibenzyl pyridine-2,4-dicarboxylate.
In stage 2, the diester is selectively hydrolyzed in position 2, for example in the presence of a copper salt as described by Delarge, Phar. Acta. Helv. 44 637 (1969).
The free acid functionality in position 2 is subsequently converted in stage 3 into the corresponding acid chloride and reacted with an alcohol such as, for example, methyl or ethyl alcohol to give the corresponding 2-carboxylic ester.
*oo C C 15 The remaining benzyl protective group in position 4 is S*eliminated by hydrogenolysis in stage 4 (for example with
H
2 /Pd, Houben-Weyl: Vol. IV/lc (1980), pp. 381 82).
The free acid in position 4 (formula II) is converted into its acid halide, preferably chloride. The acid chloride can now be converted with the amine of the formula (III) into the mixed pyridine-4-carboxamide-2carboxylic ester (IV).
The mixed diamide of the formula is prepared from the 2-carboxylic ester (IV) with alcoholic ammonia solution (for example in methanol).
The said process, which has been described in the reaction diagram for the compounds substituted in position 4, also applies to the compounds correspondingly substituted in position It is possible where appropriate for the products to be worked up, for example, by extraction or by chromatography, for example on silica gel. The isolated products 11 can be recrystallized and, where appropriate, reacted with a suitable acid to give a physiologically tolerated salt. Examples of suitable acids are: mineral acids such as hydrochloric and hydrobromic acid and sulfuric, phosphoric, nitric or perchloric acid or organic acids such as formic, acetic, propionic, succinic, glycolic, lactic, malic, tartaric, citric, maleic, fumaric, phenylacetic, benzoic, methanesulfonic, toluenesulfonic, oxalic, 4-aminobenzoic, disulfonic or ascorbic acid.
The starting compounds of the formula (III) which cannot be bought can be synthesized straightforwardly (for example Organikum, Organisch Chemisches Grundpraktikum, edition, VEB Deutscher Verlag der Wissenschaften, 15 1976; a summary of the various possibilities is to be found in the methods index, p. 822).
The compounds of the formula I according to the invention 0. have valuable pharmacological properties and, in particular, display activity as inhibitors of proline hydroxylase and lysine hydroxylase, as fibrosuppressant and immunosuppressant.
The activity of the fibrogenase can be determined by radioimmunological determination of the N-terminal propeptide of collagen type III or of the N- or Cterminal crosslinking domain of collagen type IV (7s collagen or type IV collagen NC 1 in serum.
For this purpose, the hydroxyproline, procollagen III peptide, 7s collagen and type IV collagen NCi concentrations were measured in the liver of a) untreated rats (control) b) rats given tetrachloromethane (CCl 4 control) c) rats given first CC14 and then a compound according to the invention (this test method is described by Rouille-, C., experimental toxic injury of the liver; in The 12 Liver, C. Rouiller, Vol. 2, pp. 335-476, New York, Academic Press, 1964).
By reason of these pharmacological properties, the compounds according to the invention are suitable for the treatment of disorders of the metabolism of collagen and collagen-like substances and for the treatment of disorders of the biosynthesis of Cl1 The invention therefore further relates to the use of the compounds of the formula I according to the invention, and of the physiologically tolerated salts thereof, for the treatment of the abovementioned metabolic disorders.
The compounds can be used as pharmaceuticals either alone or mixed with physiologically tolerated auxiliaries or we** vehicles. They can be administered for this purpose 15 orally in doses of 0.01 25.0 mg/kg/day, preferably 0.01 5.0 mg/kg/day or parenterally in doses of 0.001 Smg/kg/day, preferably 0.001 2.5 mg/kg/day, especially to 0.005 1.0 mg/kg/day. It is also possible to increase the dosage in severe cases. However, lower doses also suffice in many cases. These data relate to an adult weighing about 75 kg.
The invention also embraces the use of- the compounds according to the invention for preparing pharmaceuticals which are employed for the treatment and prophylaxis of the abovementioned metabolic disorders.
The invention additionally relates to pharmaceuticals which contain one or more compounds of the formula I according to the invention and/or their physiologically tolerated salts.
The pharmaceuticals are producing by processes known per se and familiar to the person skilled in the art. As pharmaceuticals, the pharmacologically active compounds active substance) according to the invention are 13 employed either as such or, preferably, in combination with suitable pharmaceutical auxiliaries or vehicles in the form of tablets, coated tablets, capsules, suppositories, emulsions, suspensions or solutions, where the content of active substance is up to 95 advantageously between 10 to 75 Suitable auxiliaries and vehicles for the required pharmaceutical formulation are, for example, besides solvents, gel formers, suppository bases, tableting auxiliaries and other active substance vehicles, also antioxidants, dispersants, emulsifiers, form suppressants, flavorings,, preservatives, solubilizers or colorants.
The active substances can be administered orally, goo 15 parenterally or rectally.
o e The active compounds are mixed with the additives suitable for this, such as vehicles, stabilizers or iner diluents, and converted by the usual methods into suitable dosage forms such as tablets, coated tablets, hard gelatin capsules, aqueous alcoholic or oily suspensions or aqueous or oily solutions. Examples of inert vehicles which can be used are gum arabic, magnesia, magnesium carbonate, potassium phosphate, lactose, glucose or starch, especially corn starch. The .25 preparation can be carried out either as dry or as wet granules. Examples of suitable oily vehicles or solvents are vegetable or animal oils, such as sunflower oil or fish liver oil.
9*o For subcutaneous or intravenous administration, the active compounds are, if required, converted into a solution, suspension or emulsion with the substances suitable for this purpose, such as solubilizers, emulsifiers or other auxiliaries. Examples of suitable solvents are physiological saline or alcohols, for example ethanol, propanol, glycerol, as well as sugar -14 solutions such as glucose or mannitol solutions, or else a mixture of the various solvents mentioned.
The invention is explained in more detail hereinafter by means of examples.
General procedure for the preparation of the compounds 1 mmol of methyl pyridine-4-carboxamide-2-carboxylate (IV) is dissolved in 30 ml of saturated methanolic amimonia solution and stirred at room temperature for 2 hours. The solution is concentrated and the residue is stirred with diisopropyl ether and filtered of f with suction.
44 Example 1 4 -N-Ethylpyridine-2 -carboxamide-4 -carboxamide Melting point: 197 0
C
a Example 2 4 -Morphol inocarboniylpyridine-2 -carboxamide Melting point: 128 0
C
Example 3 4-N ,N-Diethylpyridine-2-carboxamide-4-carboxamide Oil, MS =222 (M molecular mass C11H15N302 (221) Example 4 4-N- 2-methoxypropyl )pyridine-2-carboxamide-4-carboxamide Melting pointt 116 -120 0
C
15 Example 4-N- (3 -methoxypropyl )pyridine-2 -carboxamide-4 -carboxaxnide Melting point: 149 0
C
Example 6 4-N- 3-hydroxypropyl )pyridi.ne-2-carboxamide-4-carboxamide Melting point: 154 156 0
C
Example 7 4-N-alanylpyridine-2 -carboxamide-4-carboxamide 0.
Melting point: 124 125 0
C
10 Example 8 eel**:4-N- (O-benzylalanyl )pyridine-2-carboxamide-4-carboxamide Melting point: 138 140 0
C
COMPARATIVE EXAMPLE 1 Comparison tests have been carried out between the compound of Example 4 of the instant application (4-N-(2-methoxyethyl)-pyridine-2-carboxamide- 4-carboxamide) and the compound of Example 19 of AU-B-599746 (N,N'-Bis (2methoxyethyl) pyridine 2,4 dicarboxamide).
A further comparison was carried out between the compound of Example of the instant application (3-methoxypropyl) -pyridine-2-carboxamide-4carboxamide) and N,N' -Bis (3-methoxypropyl) -pyridine-2, 4-dicarboxamide, called Example 0 hereinafter.
The compounds of the instant invention have to be taken up by the liver.
Compounds which are slowly taken up from the liver (high t 1 /2-value) have a longer duration of action than those with a fast up-take (low tl/2-value). In the following it is shown that the compounds of the instant invention surprisingly have higher ti/2-values than the compounds disclosed by AU-B-599746.
Method: The isolated perfused rat liver: Uptake of prolylhydroxvlase proinhibitors.
Non-fasted female rats, 200-300 g, (number: N) were anaesthetized with pentobarbital (5 mg/100 g After cannulation of the portal vein, the liver was washed with 100 ml heparinized (5 IU/ml) saline of 370C for 3 minutes while the outflow occurred via the incised caudal vena cava. Subsequently, the organ was excised and connected to the perfusion apparatus and perfused with recirculating medium (100 ml) for 2 hours, 30 ml/min. Perfusion medium was I KRB* with bovine erythrocytes. Bovine blood was mixed with a citrate solution S 25 1:1 immediately in the slaughterhouse. This mixture was centrifuged minutes (6000 U/min) and the supernatant removed. The same procedure was repeated once with saline and twice with KRB. The final perfusion medium contained 33.3% of the erythrocyte sediment and 66.7% of KRB (ref.: 1).
Composition of the solutions used: 30 Citrate solution: Glucose monohydrate 22.6 g Tri-sodium citrate 4.0 g Citric acid 5.5 g N* g NaCI 4.2 g 15b add 1000 ml distilled water Krebs-Ringer-Buffer (KRB) NaCI 8.0 g KCI 0.2 g NaHCO 3 1.0 g NaH 2
PO
4
.H
2 0 0.1 g CaCI2 0.2 g MgCI 2 .6H 2 0 0.1 g Bovine Albumin 16.0 g add 898 ml distilled water and adjust to pH 7.4 Perfusion apparatus (ref.: Central element of the apparatus was a thermostatized cylinder,, with an insertable base as support of the organ. The discharge tube was elongated and the lower end of this tube was connected to a peristaltic pump. On the return of the perfusate to the organ, it passed through a heat exchanger (glass spiral) which maintained the temperature of the perfusate at 370C. The perfusate in the bottom of the cylinder was bubbled with ml gas/minute, CO 2 /0 2 mixture To avoid foam formation, 14 pl/ml 0.1% Genapol PF-10 had been added to the perfusate. Samples for analysis were withdrawn from the perfusate at a location before the perfusate entered the liver at the time points given below.
Treatments: The test compounds were added to the liver perfusate 10 minutes before mounting the liver into the perfusion apparatus in a concentration of 50 gg/ml, 3 to 5 livers were perfused for each compound.
S 25 After 0, 15, 30, 45, 60, 90 and 120 minutes, aliquots of 0.5 ml were S withdrawn from the perfusate, and the erythrocytes were removed by centrifugation. The supernatant (100 IlI) was mixed with 50 pi meta-phosphoric acid, centrifuged, and the supernatant analyzed by HPLC (Co and Ct values).
Statistical methods: Analysis of linear regression was performed after 30 log-transformation of the concentration of the compounds found in the perfusate.
Half-life times were calculated from the regression lines (ref.: according to the formula: ti/2 ((log(10co/2))-Co)/Ai [minutes] Schimassek, "Metabolite des Kohlenhydratstoffwechsels der isoliertperfundierten Rattenleber, Bihm 336:460-467 (1963).
Ryoo, and Tarver, "Studies on Plasma Protein Synthesis With a New Liver Perfusion Apparatus," PSE... 128:760-772 (1968).
Tallarida and Murray, Manual of PharmacologiujC~~Iulaionm.
Springer, New York (1981).
The results are summarized in Table 1 and Fig. 1.
Table 1 Treatment Dose N CO, al t1/2 r gig/ml Intercept Slope min Coefficent of Example 19 50 4 1,69 -0,016 19 0,997 of AU-B3-599746_____ Example 4 50 4 1,75 -0,006 50 0,994 5 Example 0 50 5 1,70 -0008 37 0,997 50 3 11,81 -0,005 601 0,974 1 Parameter of the regression lines ogCt C 0 ai t S
S
S
S
S
S
55
S
4-
Claims (9)
1. A pyridine-2,4- or -2,5-dicarboxamide of the formula I R1 0 N- R 2 C- NH 2 II 2 girc-/ -H (I) in which R1 is Cl-C 12 -alkyl, C 2 -C 12 -alkenyl or C 2 12 -alkynyl, which are unsubstituted or substituted once or, in the case of the C 2 -C 1 2 -alkyls, C2-C,-alkenyls and C 2 -C 12 a alkynyls, also several times by te** 0 '110 halogen, hydroxyl, cyano, amino, carboxyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyl- or dialkylamino, where the alkyl radicals have 1- 4 carbon atoms, or y indolyl or phenyl, which is unsubstituted or substituted once, twice or three times by halo- gen, nitro, Cl-C 4 -alkyl or C 1 -C 4 -alkoxy, it also *being possible in the case of multiple substitu- tions for the substituents to be independently S* C different from one another, 20 or R 1 is saturated C 5 -C 7 -cycloalkyl which is option- V. ally benzo-fused, or R 1 is aryl or heteroaryl, which is unsubstituted or in turn substituted once, twice or three times by halogen, nitro, cyano, Cl-C 4 -alkyl or C 1 -C 4 alkoxy, it also being possible in the case of multiple substitutions for the substituents to be independently different from one another, L 4 17 or provided that R 2 is H, R 1 is amino which is unsubstituted or mono- or disubstituted by C 1 -C 4 alkyl, phenyl or Cj-C 3 -alkylc~nrbonyl, and R2 is hydrogen or R1, where R 2 and R 1 are identical or different, or where the radicals R 1 and R 2 form, together with the nitrogen atom, a radical of the formula _N x *00) 010 in which is 1to 3and 00 *x is 0, S, CH 2 or N-R 3 where R 3 is hydrogen, ph ,,nyl or C 1 -Cr 6 -alkyl, C 2 -Cr,-alkenyl or o .:15 C 2 -Cr 6 -alkynyl, where the phenyl, alkyl, alkenyl and so:. alkynyl radicals are unsubstituted or substituted one or more times by: @000phenyl which in turn is unsubstituted. or substituted one or more times by one or more substituents selected from: halogen, nitro, cyano, carboxyl, 00 hydroxyl, methyl, ethyl, methoxy, ethoxy and 0:000:trifluoromethyl, or N(R 4 21 where R 4 is H or CI-C 3 -alkyl, i I -18 where R 5 is H or Cl-C-alkyl, or L.ON(R6). or CONHRr, where R6 is H or Cl-C3-alkyl, or where (R6)2 is a C4-C6- alkylene chain in which zero or one CH2 group which is not directly adjacent to the nitrogen atom is replaced by 0, S or N-R4 or where R 3 is Cl-C4-alkoxycarbonyl or C-C7-CYC'oalkyl, and the physiologically tolerated salts.
2. A pyridinie-2,4- or 2, 5-dicarboxamide of the formula r _I as claimed in claim 1, in which ";RR is Cl-C12-alkyl which is unsubstituted or substituted 15 once or, in the case. of the C-C2-alkyls, also several times by i phenyl hydroxyl p alkoxy alkoxyc w~ibonyl or diakylamino, where the alkyl radicals have 1-3 carbon atoms, or R1 is phenyl which is unsubstitted or in turn substituted once by halogen, nitro, cyano, methyl or methoxy, or, rovided that R2 is H, R1 is amino which Is unsubstituted or monosubstituted by Cl-C-alkyl, phenyl or Cl-C-alkylcarbonyl, and R 2 is hydrogen, 19 or where the radicals R1 and R 2 form, together with the nitrogen atom, a radical of the formula -N X in which X is O, CH 2 or N-R 3 where R 3 is hydrogen, or Ci-C 3 -alkyl, and the physiologically tolerated salts.
3. A pyridine-2,4- or -2,5-dicarboxamide of the formula 1" I as claimed in claim 1, in which R I is Ci-C 12 -alkyl which is unsubstituted or substituted once or, in the case of the Cz 2 C 12 -alkyls, also several times by phenyl, hydroxyl, alkoxy, alkoxycarbonyl, or dialkylamino, where the alkyl radicals have 1-3 carbon atoms, or R 1 is phenyl, 2 a or, provided that R 2 is H, R 1 is amino which is unsubstituted or monosubstituted by methyl- 20 carbonyl, and R 2 is hydrogen, or where the radicals R 1 and R 2 form, together with the nitrogen atom, a radical of the formula 4 4 20 -0 in which X is O, CH 2 or N-R 3 where R 3 is hydrogen, or methyl, and the physiologically tolerated salts.
4. A process for the preparation of compounds of the formula I, which comprises reacting a compound of the formula II' 04 R 10 4* 9 9~ C CH3 C-0-CH 3 0 (II') 5O 9 04 45 *4 4 with a compound of the formula III H R1 H N *R2 (III) &*se a *449 where R 1 and R 2 have the meanings indicated for formula I, and Y is halogen, especially chlorine, and subsequently converting the resulting compound of the formula IV 0 C-NR 1 R 2 f^ (IV) N CO 2 CH 3 with NH 3 into a compound of the formula I and into its physiologically tolerated salts.
A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 3 in adjunct with pharmaceutically acceptable carriers and/or excipients.
6. A method of inhibition of proline hydroxylase and lysine hydroxylase comprising administering to a patient requiring such treatment, an effective amount of a compound as claimed in any one of claims 1 to 3.
7. A method of fibrosuppression and immunosuppression comprising administering to a patient requiring such treatment, an effective amount of a compound as claimed in any one of claims 1 to 3.
8. A method of influencing the metabolism of collagen and collagen-like substances and the biosynthesis of Clq comprising administering to a patient requiring such treatment, an effective amount of a compound of the formula I as claimed in any one of claims 1 to 3.
9. A method of treatment of disorders of the metabolism of collagen and collagen-like substances and of the biosynthesis of Clq comprising administering to a patient requiring such 3. A process for the production of pharmaceuticals for influencing the metabolism of collagen and collagen-like substances and the biosynthesis of Clq, comprising admixing in a pharmacologically effective ratio, a compound of the formula I as claimed in any one of claims 1 to 3 and pharmaceutically acceptable carriers and/or excipients. o: O DATED this 2nd day of August, 1993. HOECHST AKTIENGESELLSCHAFT WATERMARK PATENT TRADEMARK ATTORNEYS THE ATRIUM 290 BURWOOD ROAD HAWTHORN VICTORIA 3122 AUSTRALIA DBM:KJS:JZ (Doc.37) AU1296792.WPC
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4108824 | 1991-03-18 | ||
| DE4108824 | 1991-03-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU1296792A AU1296792A (en) | 1992-09-24 |
| AU645668B2 true AU645668B2 (en) | 1994-01-20 |
Family
ID=6427597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU12967/92A Ceased AU645668B2 (en) | 1991-03-18 | 1992-03-17 | Mixed pyridine-2,4-and-2,5-dicarboxamides, a process for preparing them, the use thereof and pharmaceuticals based on these compounds |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0504799B1 (en) |
| JP (1) | JP3121428B2 (en) |
| KR (1) | KR100243959B1 (en) |
| AT (1) | ATE154929T1 (en) |
| AU (1) | AU645668B2 (en) |
| CA (1) | CA2063177A1 (en) |
| CZ (1) | CZ282298B6 (en) |
| DE (1) | DE59208651D1 (en) |
| DK (1) | DK0504799T3 (en) |
| ES (1) | ES2104758T3 (en) |
| FI (1) | FI101701B (en) |
| GR (1) | GR3024309T3 (en) |
| HR (1) | HRP940835A2 (en) |
| HU (1) | HU217809B (en) |
| IE (1) | IE920843A1 (en) |
| IL (1) | IL101257A (en) |
| MX (1) | MX9201156A (en) |
| NO (1) | NO178859C (en) |
| NZ (1) | NZ241968A (en) |
| TW (1) | TW199147B (en) |
| YU (1) | YU48156B (en) |
| ZA (1) | ZA921945B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU599746B2 (en) * | 1987-02-10 | 1990-07-26 | Hoechst Aktiengesellschaft | Pyridine-2,4- and -2,5-dicarboxylic acid amides, processes for their preparation, the use thereof, and medicaments based on these compounds |
| AU8485191A (en) * | 1990-10-01 | 1992-04-02 | Hoechst Aktiengesellschaft | 4- or 5-substituted pyridine-2-carboxylic acids, a process for the preparation thereof and the use thereof as pharmaceuticals |
| AU637848B2 (en) * | 1989-11-23 | 1993-06-10 | Hoechst Aktiengesellschaft | Pyridine-2,4- and 2,5-dicarboxamides, a process for the preparation thereof, and the use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE58908519D1 (en) * | 1988-08-04 | 1994-11-24 | Hoechst Ag | Improved process for the preparation of N, N-bis (alkoxyalkyl) pyridine -2,4-dicarboxylic acid diamides. |
| DE3924093A1 (en) * | 1989-07-20 | 1991-02-07 | Hoechst Ag | N, N'-BIS (ALKOXY-ALKYL) -PYRIDINE-2,4-DICARBONESAUREDIAMIDES, METHOD FOR THE PRODUCTION AND USE THEREOF |
| DE3928144A1 (en) * | 1989-08-25 | 1991-02-28 | Hoechst Ag | CYCLIC PYRIDINE-2,4- AND -2,5-DICARBONIC ACIDEDIAMIDES, METHOD FOR THE PRODUCTION AND USE THEREOF |
-
1991
- 1991-09-20 TW TW080107458A patent/TW199147B/zh active
-
1992
- 1992-03-12 YU YU24692A patent/YU48156B/en unknown
- 1992-03-16 IL IL101257A patent/IL101257A/en not_active IP Right Cessation
- 1992-03-16 FI FI921119A patent/FI101701B/en active
- 1992-03-16 IE IE084392A patent/IE920843A1/en unknown
- 1992-03-16 NZ NZ241968A patent/NZ241968A/en unknown
- 1992-03-17 EP EP92104584A patent/EP0504799B1/en not_active Expired - Lifetime
- 1992-03-17 NO NO921025A patent/NO178859C/en not_active IP Right Cessation
- 1992-03-17 CZ CS92803A patent/CZ282298B6/en unknown
- 1992-03-17 CA CA002063177A patent/CA2063177A1/en not_active Abandoned
- 1992-03-17 DE DE59208651T patent/DE59208651D1/en not_active Expired - Fee Related
- 1992-03-17 ES ES92104584T patent/ES2104758T3/en not_active Expired - Lifetime
- 1992-03-17 AU AU12967/92A patent/AU645668B2/en not_active Ceased
- 1992-03-17 KR KR1019920004320A patent/KR100243959B1/en not_active IP Right Cessation
- 1992-03-17 DK DK92104584.5T patent/DK0504799T3/en active
- 1992-03-17 MX MX9201156A patent/MX9201156A/en unknown
- 1992-03-17 HU HU9200891A patent/HU217809B/en not_active IP Right Cessation
- 1992-03-17 ZA ZA921945A patent/ZA921945B/en unknown
- 1992-03-17 JP JP04060053A patent/JP3121428B2/en not_active Expired - Fee Related
- 1992-03-17 AT AT92104584T patent/ATE154929T1/en not_active IP Right Cessation
-
1994
- 1994-10-26 HR HRP-246/92A patent/HRP940835A2/en not_active Application Discontinuation
-
1997
- 1997-07-30 GR GR970401958T patent/GR3024309T3/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU599746B2 (en) * | 1987-02-10 | 1990-07-26 | Hoechst Aktiengesellschaft | Pyridine-2,4- and -2,5-dicarboxylic acid amides, processes for their preparation, the use thereof, and medicaments based on these compounds |
| AU637848B2 (en) * | 1989-11-23 | 1993-06-10 | Hoechst Aktiengesellschaft | Pyridine-2,4- and 2,5-dicarboxamides, a process for the preparation thereof, and the use thereof |
| AU8485191A (en) * | 1990-10-01 | 1992-04-02 | Hoechst Aktiengesellschaft | 4- or 5-substituted pyridine-2-carboxylic acids, a process for the preparation thereof and the use thereof as pharmaceuticals |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5130317A (en) | Pyrimidine-4,6-dicarboxylic acid diamides, processes for the use thereof, and pharmaceuticals based on these compounds | |
| US5260323A (en) | 2,4- and 2,5-substituted pyridine-N-oxides, processes for their preparation and their use | |
| EP1073641B1 (en) | New substituted amides, their production and their use | |
| US5037839A (en) | Pyridine-2,4-and -2,5-dicarboxylic acid amides and medicaments based on these compounds | |
| NZ238701A (en) | 2,4- and 2,5-substituted pyridine-n-oxides and pharmaceutical compositions | |
| IE913435A1 (en) | 4- or 5-substituted pyridine-2-carboxylic acids, a process¹for the preparation thereof and the use thereof as¹pharmaceuticals | |
| AU645668B2 (en) | Mixed pyridine-2,4-and-2,5-dicarboxamides, a process for preparing them, the use thereof and pharmaceuticals based on these compounds | |
| SK279199B6 (en) | N,n'-bis-(alkoxyalkyl)-pyridine-2,4-dicarboxylic acid diamides, a process of preparation and use thereof, pharmaceutical compositions containing the same | |
| JPH10175967A (en) | New n-benzylpiperazine compound, its production and pharmaceutical composition containing the compound | |
| US5455259A (en) | Compounds for the treatment of neurodegenerative disorders | |
| US5512586A (en) | Medicaments based on pyridine-2,4- and 2,5-dicarboxylic acid amides | |
| US5364873A (en) | Pyridine-2,4- and dicarboxylic acid derivatives, the use thereof and pharmaceutical composition based on these compounds | |
| US5153208A (en) | Pyridine-2,4- and -2,5-dicarboxylic acid amides and their medicinal compositions and methods of use | |
| JPH0390061A (en) | Cyclic pyridine-2,4-or-2, 5-dicarboxylic acid diamine | |
| US5614537A (en) | 2,4-and 2,5-bistetrazolylpyridines, a process for the preparation thereof and the use thereof as pharmaceuticals | |
| AU637848B2 (en) | Pyridine-2,4- and 2,5-dicarboxamides, a process for the preparation thereof, and the use thereof | |
| IE913436A1 (en) | 4- or 5-substituted pyridine-2-carboxylic acids, a process¹for the preparation thereof and the use thereof as¹pharmaceuticals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |